Selenium targets resistance biomarkers enhancing efficacy while reducing toxicity of anti-cancer drugs: preclinical and clinical development

por Zakharia, Yousef, Bhattacharya, Arup, Rustum, Youcef M.
Publicado 2018

Druggable Biomarkers Altered in Clear Cell Renal Cell Carcinoma: Strategy for the Development of Mechanism-Based Combination Therapy

por Rustum, Youcef M., Reis, Ryan, Rustum, Tara M.
Publicado 2023

Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma—Bench-to-Bedsi...

por Rustum, Youcef M., Chintala, Sreenivasulu, Durrani, Farukh A., Bhattacharya, Arup
Publicado 2018

Targeting the oncogenic protein beta-catenin to enhance chemotherapy outcome against solid human cancers

por Saifo, Maher S, Rempinski, Donald R, Rustum, Youcef M, Azrak, Rami G
Publicado 2010

A Novel Small Molecule FL118 That Selectively Inhibits Survivin, Mcl-1, XIAP and cIAP2 in a p53-Independent Manner, Shows Superior Antitumor Activity

por Ling, Xiang, Cao, Shousong, Cheng, Qiuying, Keefe, James T., Rustum, Youcef M., Li, Fengzhi
Publicado 2012

Potential Role of Selenium in the Treatment of Cancer and Viral Infections

por Rataan, Aseel O., Geary, Sean M., Zakharia, Yousef, Rustum, Youcef M., Salem, Aliasger K.
Publicado 2022

Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor...

por Chintala, Sreenivasulu, Najrana, Tanbir, Toth, Karoly, Cao, Shousong, Durrani, Farukh A, Pili, Roberto, Rustum, Youcef M
Publicado 2012

MicroRNA Expression in Clear Cell Renal Cell Carcinoma Cell Lines and Tumor Biopsies: Potential Therapeutic Targets

por Swearson, Samuel, Rataan, Aseel O., Eliason, Steven, Amendt, Brad A., Zakharia, Yousef, Salem, Aliasger K., Ho, Thai, Rustum, Youcef M.
Publicado 2022

Architectural Heterogeneity in Tumors Caused by Differentiation Alters Intratumoral Drug Distribution and Affects Therapeutic Synergy of Antiangiogenic Organoselenium Compound

por Rustum, Youcef M., Tóth, Károly, Seshadri, Mukund, Sen, Arindam, Durrani, Farukh A., Stott, Emily, Morrison, Carl D., Cao, Shousong, Bhattacharya, Arup
Publicado 2010

Selenium is a modulator of circadian clock that protects mice from the toxicity of a chemotherapeutic drug via upregulation of the core clock protein, BMAL1

por Hu, Yan, Spengler, Mary L., Kuropatwinski, Karen K., Comas, Maria, Jackson, Marilyn, Chernov, Mikhail V., Gleiberman, Anatoly S., Fedtsova, Natalia, Rustum, Youcef M., Gudkov, Andrei V., Antoch, Marina P.
Publicado 2011